Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease
Despite prior biologic exposure and frequent dose escalation, switching to ustekinumab biosimilar showed stable efficacy, unchanged biomarkers, and high treatment persistence.
Authors
- Waqqas Afif (ORCID: https://orcid.org/0000-0001-6869-0982)
- Talat Bessissow (ORCID: https://orcid.org/0000-0003-2610-1910)
- Justin Kritzinger (ORCID: https://orcid.org/0000-0003-1046-6683)
- Gary Wild (ORCID: https://orcid.org/0000-0002-9625-3437)
- Gynter Kotrri
- Huzaifa Nadeem (ORCID: https://orcid.org/0009-0004-9339-2329)
- Alain Bitton
- Peter Laszlo Lakatos
- Ivanna Candel
Institutions
- Semmelweis University (HU)
- McGill University Health Centre (CA)
- McGill University (CA)
Publication Details
- Journal
- World Journal of Gastroenterology
- Published
- 2025-12-26
- DOI
- https://doi.org/10.3748/wjg.v31.i48.114355
- Citations
- 1
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.80